Pharmacokinetic studies of multi-bioactive components in rat plasma after oral administration of Xin

来源 :中草药(英文版) | 被引量 : 0次 | 上传用户:jrno1213
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective:To investigate the in vivo pharmacokinetic characteristics of 17 bioactive components including ginsenoside Rg1,Rb1,Rd,berberine,epiberberine,jatrorthizine,palmatine,columbamine,coptisine,evodiamine,dehydroevodiamine,rutaecarpine,limonin,hyperin,curcumin,demethoxycurcumin and bisdemethoxycurcumin in rat plasma after oral administration of Xintiantai I extract powder (Ⅺ) and Xintiantai I without guide drug beol extract powder (Ⅺ without beol),and study the compatibility effects of guide drug beol on the pharmacokinetics.Methods:A UHPLC-MS/MS method was established and fully validated for the comparative pharmacokinetics of 17 bioactive components.The pharmacokinetics parameters of 17 bioactive components after oral administration of Ⅺ and Ⅺ without beol were calculated by the software of DAS 3.0 and intercompared.Results:The specificity,linearity,lower limit of quantification (LLOQ),precision,accuracy,extraction recovery rates,matrix effects,and stability of the UHPLC-MS/MS assay were good within the acceptance criteria from FDA guidelines.Guide drug beol can significantly increase AUC of G-Rd,palmatine,hyperin,curcumin,demethoxycurcumin,bisdemethoxycurcumin and Cmax of 16 bioactive components except for dehydroevodiamine (P < 0.05),decrease Tmax of G-Rd,berberine,columbamin,coptisine,limonin and MRT of 17 bioactive components in Ⅺ group (P < 0.05).Conclusion:Guide drug beol enhanced the absorption of G-Rd,palmatine,hyperin,curcumin,demethoxycurcumin and bisdemethoxycurcumin.
其他文献
这是一个令人欢喜令人忧的时代,颠覆发生得太快,让人目不暇接。  颠覆的“大时代”  上世纪90年代,摩托罗拉在中国寻呼机市场切到了70%的蛋糕,它的大哥大也占据半壁江山。到21世纪初,它就被不断推出新品的诺基亚、三星逼到死角。诺基亚也没风光几年,又被卖电脑的苹果秒杀了。当然,干掉诺基亚的苹果在中国并非一枝独秀,因为中国本土品牌的手机正迅速崛起。  再看电商。马云说:“游戏已经开始了。”他所谓的游戏
Objective:To investigate the therapeutic effect of total iridoid glycosides of Picrorhiza scrophulariiflora (TIGP) on non-alcoholic steatohepatitis (NASH).Metho